This study aimed at finding the relationship between the level of expression of the PRR11
protein in
pancreatic carcinoma, and the clinical characteristics of the
tumor. PCR technique was used to analyze the expression levels of the PRR11 gene in 38 samples from
pancreatic cancer patients and 10 samples from normal pancreatic tissues. Western blot analysis and immunohistochemistry were used to measure the expression of the PRR11. Additionally, the migration ability of cancerous cells expressing PRR11 and those with inhibited expression were compared using a wound healing assay. Finally, the relationships between the expression level of PRR11
protein and variables such as
tumor size,
tumor invasion, TNM stages, and the overall survival time of patients with
pancreatic cancer were calculated. Our results showed the expression level of the PRR11 gene in
pancreatic cancer tissues was significantly higher than that in normal pancreatic tissues. The detection of PRR11
protein in
cancer tissues versus normal tissues was 78.9 (30/38) vs. 0 (0/10), respectively. The western blot results confirmed this by showing a significantly higher level of expression of the PRR11
protein in
pancreatic cancer tissues than in normal tissues (P<0.05). Inhibiting the expression of PRR11 in
cancer cells reduced the migration ability of the cells. Finally, the expression of PRR11 was positively correlated with the invasion, disease and tissue differentiation stages of the
pancreatic cancer. By comparing clinical data and expression patterns in patients, we found the survival rate in those expressing the PRR11
protein by immunohistochemistry to be lower than in those with tissues negative to the PRR11
protein. Our results show, the expression of PRR11
protein in
pancreatic cancer is closely related to the development of the
cancer and a poor prognosis. These findings provide a theoretical and experimental basis for approaching the diagnosis and treatment of
pancreatic cancer using PRR11 as a molecular target.